COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors

Signal Transduct Target Ther. 2021 Dec 16;6(1):427. doi: 10.1038/s41392-021-00822-x.

Abstract

Abnormal glucose and lipid metabolism in COVID-19 patients were recently reported with unclear mechanism. In this study, we retrospectively investigated a cohort of COVID-19 patients without pre-existing metabolic-related diseases, and found new-onset insulin resistance, hyperglycemia, and decreased HDL-C in these patients. Mechanistically, SARS-CoV-2 infection increased the expression of RE1-silencing transcription factor (REST), which modulated the expression of secreted metabolic factors including myeloperoxidase, apelin, and myostatin at the transcriptional level, resulting in the perturbation of glucose and lipid metabolism. Furthermore, several lipids, including (±)5-HETE, (±)12-HETE, propionic acid, and isobutyric acid were identified as the potential biomarkers of COVID-19-induced metabolic dysregulation, especially in insulin resistance. Taken together, our study revealed insulin resistance as the direct cause of hyperglycemia upon COVID-19, and further illustrated the underlying mechanisms, providing potential therapeutic targets for COVID-19-induced metabolic complications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • COVID-19 / blood*
  • COVID-19 / complications
  • Female
  • Humans
  • Hyperglycemia / blood*
  • Hyperglycemia / etiology
  • Insulin Resistance*
  • Lipid Metabolism*
  • Lipids / blood*
  • Male
  • Middle Aged
  • Retrospective Studies
  • SARS-CoV-2 / metabolism*

Substances

  • Biomarkers
  • Lipids